Pair Name	Berberine, Erlotinib
Partner Name	Erlotinib
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	EGFR	hsa1956
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	CCND1	hsa595
In Vitro Model	A-431	Skin squamous cell carcinoma	Homo sapiens (Human)	CVCL_0037
	NCI-H1666	Minimally invasive lung adenocarcinoma	Homo sapiens (Human)	CVCL_1485
	NCI-H441	Lung papillary adenocarcinoma	Homo sapiens (Human)	CVCL_1561
	NCI-H1781	Minimally invasive lung adenocarcinoma	Homo sapiens (Human)	CVCL_1494
In Vivo Model	A431 cells (5×10⁶) were suspended in 200 µL of normal saline and subcutaneously implanted into 6-7-week-old male athymic nude mice.
Result	Our data supported use of BBR in combination with erlotinib as a novel strategy for treatment of patients with EGFR positive tumors.

Pair Name	Berberine, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2B51]	Osteosarcoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CDK4	hsa1019
	Down-regulation	Phosphorylation	MAPK14	hsa1432
	Down-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Phosphorylation	MAPK1	hsa5594
In Vitro Model	MG-63	Osteosarcoma	Homo sapiens (Human)	CVCL_0426
Result	Berberine and Cisplatin Exhibit Synergistic Anticancer Effects on Osteosarcoma MG-63 Cells by Inhibiting the MAPK Pathway

Pair Name	Berberine, Niraparib
Partner Name	Niraparib
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Expression	RAD51	hsa5888
	Down-regulation	Expression	NR1H4	KEGG ID N.A.
	Up-regulation	Phosphorylation	H2AX	hsa3014
In Vitro Model	A2780	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_0134
	HO-8910	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_6868
In Vivo Model	The animals were subcutaneously inoculated with 1 × 106 A2780 cells (suspended in 100 μl PBS) and six days later the tumor-bearing mice were randomly divided into four groups and were then treated daily by oral gavage with vehicle (sodium carboxymethycellulose, SCMC), berberine (200 mg/kg bodyweight), niraparib (40 mg/kg bodyweight) and berberine (200 mg/kg) in combination with niraparib (40 mg/kg), respectively, for 15 days.
Result	The results indicate that by inducing oxidative DNA damage and downregulating HRR in cancer cells berberine is able to further sensitize cancer cells to PARP inhibition. These results demonstrate a potential therapeutic value of combined application of berberine and PARP inhibitors in ovarian cancer treatment.

Pair Name	Berberine, Letrozole
Partner Name	Letrozole
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	Our results suggest that concomitant treatment of LTZ-BBR increases the efficacy of chemotherapeutic agents with low BBR concentrations, especially in chemo-resistant malignancies.

Pair Name	Berberine, Lapatinib
Partner Name	Lapatinib
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->ROS generation
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Expression	NFE2L2	hsa4780
In Vitro Model	BT-474LabR	Lapatinib-resistant breast adenocarcinoma	Homo sapiens (Human)	N.A.
	AU-565LapR	Lapatinib-resistant breast adenocarcinoma	Homo sapiens (Human)	N.A.
Result	Berberine can upset the ROS balance by downregulating c-Myc to reverse the Lapatinib resistance. Our finding provides a novel strategy of using berberine to overcome Lapatinib resistance.